| aspirin versus no treatment | |||
| WASH (aspirin), 2004 | aspirin 300 mg/day versus no treatment | patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy with LVEF<=35% | open Follow-up duration: 27 months UK, US |
| aspirin versus placebo | |||
| Barzizza (ASA), 1993 | aspirin 300mg versus placebo | patients with dilated cardiomyopathy and evidence of intraventricular thrombi | NA Follow-up duration: 6 months |
| rivaroxaban versus placebo | |||
| COMMANDER HF, 2018 NCT01877915 | rivaroxaban at a dose of 2.5 mg twice daily versus placebo | patients who had chronic heart failure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation | Follow-up duration: 21.1 months |
| warfarin versus aspirin | |||
| HELAS (warfarin vs aspirin), 2006 | warfarin versus aspirin 325mg/d | HF related to ischemic heart disease with LVFE<35% | Double blind Follow-up duration: 21.9 months Europe |
| WATCH (warfarin vs aspirin), 2009 NCT00007683 | warfarin (target INR 2.5-3.0) versus aspirin 162 mg daily | symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics | open |
| warfarin versus no treatment | |||
| WASH (warfarin), 2004 | warfarin (target INR 2.5) versus no treatment | patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy with LVEF<=35% | open Follow-up duration: 27 months UK, US |
| warfarin versus placebo | |||
| HELAS (warfarin vs placebo), 2006 | warfarin (target
INR of 2–3) versus placebo | HF due to dilated cardiomyopathy | double blind Follow-up duration: 21.9 months Europe |
| Barzizza (warfarin), 1993 | warfarin to maintain INR between 2 and 3 versus placebo | patients with dilated cardiomyopathy and evidence of intraventricular thrombi | NA Follow-up duration: 6 months |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
